Noam Peleg1, Assaf Issachar2, Orly Sneh-Arbib1, Amir Shlomai3. 1. Department of Medicine D and the Liver Institute, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel. 2. Department of Medicine D and the Liver Institute, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Department of Medicine D and the Liver Institute, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: shlomaiamir@gmail.com.
Abstract
BACKGROUND & AIMS: Liver fibrosis is the single most important prognostic factor in patients with non-alcoholic fatty liver disease (NAFLD). The predictive value of the AST to Platelet Ratio Index (APRI) score, originally developed for fibrosis assessment in hepatitis C virus (HCV) patients, is much less known in the context of NAFLD patients. METHODS: We retrospectively compared the performance of APRI and fibrosis 4 calculator (FIB-4) scores in NAFLD patients with documented liver biopsies, to their performance in chronic HCV patients. RESULTS: 153 patients with biopsy-proven NAFLD and 297 patients with biopsy-proven chronic HCV infection were included. The APRI score was a good predictor for advanced fibrosis in NAFLD patients (area under the ROC curve 0.8307) although it was modestly inferior as compared to the well-validated FIB-4 score (area under the ROC curve 0.8959). The predictive value of APRI score in NALFD patients was inferior as compared to its predictive value in HCV patients (area under the ROC curve of 0.8307 versus 0.9965). In contrast to FIB-4, APRI score was not a good discriminator between intermediate stages of fibrosis in NAFLD patients. CONCLUSIONS: APRI and Fib-4 scores are reasonable tools to allocate NAFLD patients with advanced fibrosis. FIB-4 may better discriminate between intermediate fibrosis stages.
BACKGROUND & AIMS:Liver fibrosis is the single most important prognostic factor in patients with non-alcoholic fatty liver disease (NAFLD). The predictive value of the AST to Platelet Ratio Index (APRI) score, originally developed for fibrosis assessment in hepatitis C virus (HCV) patients, is much less known in the context of NAFLD patients. METHODS: We retrospectively compared the performance of APRI and fibrosis 4 calculator (FIB-4) scores in NAFLD patients with documented liver biopsies, to their performance in chronic HCVpatients. RESULTS: 153 patients with biopsy-proven NAFLD and 297 patients with biopsy-proven chronic HCV infection were included. The APRI score was a good predictor for advanced fibrosis in NAFLD patients (area under the ROC curve 0.8307) although it was modestly inferior as compared to the well-validated FIB-4 score (area under the ROC curve 0.8959). The predictive value of APRI score in NALFD patients was inferior as compared to its predictive value in HCVpatients (area under the ROC curve of 0.8307 versus 0.9965). In contrast to FIB-4, APRI score was not a good discriminator between intermediate stages of fibrosis in NAFLD patients. CONCLUSIONS: APRI and Fib-4 scores are reasonable tools to allocate NAFLD patients with advanced fibrosis. FIB-4 may better discriminate between intermediate fibrosis stages.
Authors: Alejandro Campos-Murguía; Astrid Ruiz-Margáin; José A González-Regueiro; Ricardo U Macías-Rodríguez Journal: World J Gastroenterol Date: 2020-10-21 Impact factor: 5.742
Authors: Carlo Torti; Vincenzo Scaglione; Bruno Mario Cesana; Chiara Costa; Nadia Marascio; Elisabetta Schiaroli; Chiara Busti; Sabrina Bastianelli; Maria Mazzitelli; Enrico Maria Trecarichi; Daniela Francisci Journal: Health Sci Rep Date: 2021-05-02
Authors: Neal S Parikh; Hooman Kamel; Babak B Navi; Costantino Iadecola; Alexander E Merkler; Arun Jesudian; Jesse Dawson; Guido J Falcone; Kevin N Sheth; David J Roh; Mitchell S V Elkind; Daniel F Hanley; Wendy C Ziai; Santosh B Murthy Journal: Stroke Date: 2020-01-07 Impact factor: 7.914